Tolvaptan
FDA-approved product (tablet, oral), marketed as Jynarque, Samsca, Tolvaptan.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Autosomal dominant polycystic kidney disease
- Cardiovascular disease
- Congestive heart failure
- Heart failure
- Hyponatremia
- Inappropriate ADH syndrome
- Polycystic Kidney Disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Vasopressin antagonists
- FDA pharmacologic class
- Vasopressin V2 Receptor Antagonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA60.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli44.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae19.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis70.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Tolvaptan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm95.6% AI-predicted activityagainst MRSALab records exist50+ registered studies
- TaurursodiolExisting use: Bile acids and derivatives79.6% AI-predicted activityagainst MRSA43 registered studies
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome74.5% AI-predicted activityagainst MRSA50+ registered studies
- PlecanatideExisting use: Constipation74.4% AI-predicted activityagainst MRSA15 registered studies
- OxytocinExisting use: Hemorrhage, Uterine Inertia74.2% AI-predicted activityagainst MRSA50+ registered studies
- PosaconazoleExisting use: Aspergillosis, Candidiasis, Coccidioidomycosis and 2 more72.2% AI-predicted activityagainst MRSA50+ registered studies
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma70.6% AI-predicted activityagainst MRSA50+ registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more70.1% AI-predicted activityagainst MRSA50+ registered studies
- Quizartinib DihydrochlorideExisting use: Acute myeloid leukemia, Myeloid leukemia70.0% AI-predicted activityagainst MRSA4 registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more70.0% AI-predicted activityagainst MRSA50+ registered studies
- Deoxycholic AcidExisting use: Other dermatologicals69.3% AI-predicted activityagainst MRSA50+ registered studies
- ChenodiolExisting use: Cerebrotendinous xanthomatosis, Inborn errors of metabolism69.2% AI-predicted activityagainst MRSA30 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)
NCT00234104 · start 2004-08
Registered record
- Registry ID
- NCT00234104
- Conditions
- Heart Failure, Congestive; Edema
- Interventions
- OPC-41061(Tolvaptan)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2004-08
- Completion
- 2006-01
- Enrolment
- 122
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHeart Failure, Congestive; EdemaInterventionOPC-41061(Tolvaptan)PhasePhase 2Registry statusCompletedEVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan
NCT00071331 · start 2003-09
Registered record
- Registry ID
- NCT00071331
- Conditions
- Congestive Heart Failure
- Interventions
- Tolvaptan
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-09
- Completion
- 2006-07
- Enrolment
- 3,600
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCongestive Heart FailureInterventionTolvaptanPhasePhase 3Registry statusCompleted"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia
NCT00072683 · start 2003-04-01
Registered record
- Registry ID
- NCT00072683
- Conditions
- Hyponatremias; Water Intoxication; Inappropriate ADH Syndrome; Water-Electrolyte Imbalances
- Interventions
- tolvaptan; placebo matching tolvaptan
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-04-01
- Completion
- 2005-12-01
- Enrolment
- 205
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHyponatremias; Water Intoxication; Inappropriate ADH Syndrome; Water-Electrolyte ImbalancesInterventiontolvaptan; placebo matching tolvaptanPhasePhase 3Registry statusCompletedMulticenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients
NCT00043758 · start 2002-07
Registered record
- Registry ID
- NCT00043758
- Conditions
- Congestive Heart Failure
- Interventions
- Tolvaptan
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-07
- Completion
- 2004-07
- Enrolment
- 170
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCongestive Heart FailureInterventionTolvaptanPhasePhase 2Registry statusCompletedAcute Heart Failure Patients With High Copeptin Treated With Tolvaptan Targets Increased AVP Activation for Treatment (ACTIVATE)
NCT01733134
Registered record
- Registry ID
- NCT01733134
- Conditions
- Acute Heart Failure
- Interventions
- Tolvaptan; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Withdrawn
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Heart FailureInterventionTolvaptan; placeboPhasePhase 3Registry statusWithdrawn